Development-stage biopharmaceutical company SparX Biopharmaceutical Corp announced on Friday that it will present a clinical update on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress poster session at the 2025 American Association for Cancer Research (AACR) Annual Meeting on 28 April.

The presentation marks the one-year anniversary of the first patient dosing of this novel bispecific antibody in an ongoing Phase 1 clinical trial.

A more comprehensive overview of SPX-303's dual mechanism, which targets both myeloid and T-cell immune checkpoints, will be featured at a Satellite Symposium themed 'Harnessing Super Immunotherapy and ADCs to Redefine the Standard of Care'. Co-hosted by the University of Illinois at Chicago Cancer Center and Yao Yuan--Academy for Pharma Innovation, the symposium will bring together expert clinicians, academic investigators and industry leaders to discuss how next-generation immuno-oncology, known as 'Super IO', can be synergised with antibody-drug conjugates (ADCs). This innovative approach combines the tumour-targeting precision of ADCs with the immune-activating power of checkpoint inhibitors, with the intention of delivering deeper and more durable anti-tumour responses.

SPX-303, a first-in-class bispecific antibody targeting LILRB2 and PD-L1, is currently enrolling patients with resistant or refractory solid tumours at a dose level of 20 mg/kg.

"This innovative programme represents a significant advancement in macrophage checkpoint blockade and T cell co-engagement strategies," said Dr. Gui-Dong Zhu, CEO of SparX. "It holds promise as a potential next-generation immuno-oncology therapy -- or 'Super IO' booster -- for patients with limited treatment options."